CDR-Life Announces Fifth Milestone Achievement with Boehringer Ingelheim in Geographic Atrophy

ZÜRICH--(BUSINESS WIRE)--CDR-Life today announced the achievement of the fifth milestone under its collaboration and licensing agreement with Boehringer Ingelheim in the advancement of BI 771716, a novel therapeutic candidate for the treatment of geographic atrophy (GA), a leading cause of vision loss. This milestone follows successful Phase 1 results demonstrating a favorable safety profile for BI 771716 across both single and multiple intravitreal doses. The program has advanced into Phase 2